Walgreen (WAG) November Comps Sag 6.2%
Tweet
Share
E-mail
Walgreen Company (NYSE: WAG) November sales in comparable stores decreased by 6.2 percent, versus the estimate of a 1.3 percent decrease.
Total November sales were $5.85 billion, a decrease of 3.9 percent from $6.09 billion for the same month in fiscal 2012.
Total front-end sales decreased 0.3 percent compared with the same month in fiscal 2012, while comparable store front-end sales decreased 1.7 percent. Customer traffic in comparable stores decreased 4.9 percent while basket size increased 3.2 percent.
Prescriptions filled at comparable stores decreased by 2.9 percent in November and by a day-fall adjusted (DFA) 2.6 percent.
November pharmacy sales decreased 4.7 percent, while comparable store pharmacy sales decreased 8.8 percent.
Flu shots administered at pharmacies and clinics season-to-date were nearly 4.6 million versus approximately 5 million last year.
Total November sales were $5.85 billion, a decrease of 3.9 percent from $6.09 billion for the same month in fiscal 2012.
Total front-end sales decreased 0.3 percent compared with the same month in fiscal 2012, while comparable store front-end sales decreased 1.7 percent. Customer traffic in comparable stores decreased 4.9 percent while basket size increased 3.2 percent.
Prescriptions filled at comparable stores decreased by 2.9 percent in November and by a day-fall adjusted (DFA) 2.6 percent.
November pharmacy sales decreased 4.7 percent, while comparable store pharmacy sales decreased 8.8 percent.
Flu shots administered at pharmacies and clinics season-to-date were nearly 4.6 million versus approximately 5 million last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IM Cannabis director Alon Dayan resigns for personal reasons
- Loop Capital Starts CrowdStrike (CRWD) at Buy
- Western Union chief legal officer to retire in November 2026
Create E-mail Alert Related Categories
Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
